Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/rmv.2271 http://scihub22266oqcxt.onion/10.1002/rmv.2271 34228851!8420234!34228851     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Med+Virol 2022 ; 32 (2): e2271 Nephropedia Template TP {{tp|p=34228851|t=2022. Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis |pdf=|usr=}}{{34228851}} gab.com Text Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis JO: Rev Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=34228851 #FOAvip We estimated the seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in residents of African countries and explored its associated factors. We searched PubMed, EMBASE, PsycINFO, AMED, CINAHL, DOAJ and Google Scholar databases for peer reviewed articles and pre-prints that reported anti-SARS-CoV-2 antibody seroprevalence of general or specific human populations resident in Africa. The eligible studies were evaluated using Joana Briggs Institute prevalence critical appraisal tool. Twenty-three studies involving 27,735 individuals were included in our paper. The pooled seroprevalence of anti-SARS-CoV-2 antibodies in Africa was 22% (95%CI: 14-31) with very high heterogeneity (I(2) = 100%, p < 0.001). Seroprevalence was highest in studies conducted in Central Africa compared to Southern Africa, West Africa, North Africa and East Africa respectively. The number of days between the first reported coronavirus disease 2019 case in each country and when a seroprevalence study was conducted was a significant moderator of seroprevalence. Seropositivity was numerically influenced by gender and age of the participants with males and those aged below 50 years being most affected with SARS-CoV-2 infection. The highest pooled seroprevalence in Africa reported in this review should be interpreted cautiously due to high heterogeneity between studies. Continued seroprevalence surveillance is warranted to establish Africa's transition towards herd immunity. Twit Text FOAVip Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis ????Rev Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=34228851 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34228851 #FOAvip English Wikipedia <ref>{{Cite pmid|34228851}}</ref> Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis #MMPMID34228851 Chisale MRO; Ramazanu S; Mwale SE; Kumwenda P; Chipeta M; Kaminga AC; Nkhata O; Nyambalo B; Chavura E; Mbakaya BC Rev Med Virol 2022[Mar]; 32 (2): e2271 PMID34228851show ga We estimated the seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in residents of African countries and explored its associated factors. We searched PubMed, EMBASE, PsycINFO, AMED, CINAHL, DOAJ and Google Scholar databases for peer reviewed articles and pre-prints that reported anti-SARS-CoV-2 antibody seroprevalence of general or specific human populations resident in Africa. The eligible studies were evaluated using Joana Briggs Institute prevalence critical appraisal tool. Twenty-three studies involving 27,735 individuals were included in our paper. The pooled seroprevalence of anti-SARS-CoV-2 antibodies in Africa was 22% (95%CI: 14-31) with very high heterogeneity (I(2) = 100%, p < 0.001). Seroprevalence was highest in studies conducted in Central Africa compared to Southern Africa, West Africa, North Africa and East Africa respectively. The number of days between the first reported coronavirus disease 2019 case in each country and when a seroprevalence study was conducted was a significant moderator of seroprevalence. Seropositivity was numerically influenced by gender and age of the participants with males and those aged below 50 years being most affected with SARS-CoV-2 infection. The highest pooled seroprevalence in Africa reported in this review should be interpreted cautiously due to high heterogeneity between studies. Continued seroprevalence surveillance is warranted to establish Africa's transition towards herd immunity. |*COVID-19/epidemiology[MESH] |Africa, Southern[MESH] |Aged[MESH] |Antibodies, Viral[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2[MESH]Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic r(epmc).pdf DeepDyve Pubget Overpricing